The Global Urinary Tract Infection Treatment Industry is poised for remarkable expansion, with a projected valuation of US$13,617.4 million by the year 2034. According to the latest market analysis, the sector is estimated to be valued at US$11,244.0 million in 2024, reflecting a robust Compound Annual Growth Rate (CAGR) of 1.9% over the next decade.
This unprecedented growth is indicative of the increasing prevalence of urinary tract infections and the escalating demand for advanced and effective treatment solutions. The forecasted CAGR from 2024 to 2034 underscores the steady rise in the scope and market potential for UTI treatment.
Launch of New Antibiotics for Bacterial Infections to Sustain Revenues
An increase in the number of research and development initiatives for developing novel therapeutics has led to the launch of new drugs into the Global Urinary Tract Infection Treatment Industry. Manufacturers are currently focusing on expanding their pipeline portfolio for the treatment of bacterial infections. Moreover, regulatory bodies such as the FDA have accelerated the approval process of drugs.
Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-1340
Recently, in August 2018, Melinta Therapeutics announced the launch of Vabomere (meropenem and vaborbactam) for patients who require treatment for complicated urinary tract infections. Similarly, one more drug was approved by the FDA in June 2018, Zemdri by Achaogen, Inc., for the treatment of adults suffering from Complicated Urinary Tract infections (cUTI). An increase in the launch and approval of novel therapeutics for the treatment of bacterial infections is expected to contribute to the growth of the Global Urinary Tract Infection Treatment Industry.
Quinolones, the broad-spectrum antibiotics effective against a wide range of bacterial diseases, have bactericidal activity that enables them to penetrate deep into the tissue. Their excellent bioavailability is a plus point. In addition, they have favorable tolerability and safety profile. Moreover, they have significant antimicrobial activity. Thus, quinolones are most preferred for the treatment of urinary tract infections. Some of the widely used quinolones for the prevention of bacterial infection include ciprofloxacin (Cipro), ofloxacin (Floxin), norfloxacin (Noroxin), and others. Quinolones are mostly favored over trimethoprim-sulfamethoxazole (TMP-SMX) for the treatment of uncomplicated urinary tract infections owing to the increasing resistance of bacteria towards antibiotics such as trimethoprim-sulfamethoxazole, beta-lactam antibiotics, and others
Europe Remains a Major Revenue Contributor
Europe holds a considerable revenue share in the UTI treatment market. The rising prevalence of urinary tract infections among the population and increasing hospital visits are among the factors that are likely to propel the growth of the urinary tract infection treatment market. It is estimated that the urinary tract infection treatment market will create an incremental $ opportunity worth nearly US$ 9 M between 2019 and 2029. Quinolones are anticipated to boost the growth of the urinary tract infection treatment market owing to the increasing prescription and high effectiveness as antimicrobial antibiotics.
Have a Conversation with the Analyst
https://www.futuremarketinsights.com/ask-question/rep-gb-1340
Demand from Retail Pharmacies to Register High Growth
The Global Urinary Tract Infection Treatment Industry has been segmented based on drug class, indication, and distribution channel. Based on drug class, the urinary tract infection treatment market has been segmented into Penicillin and combinations, Quinolones, Cephalosporin, Aminoglycoside Antibiotics, Sulphonamides (Sulfamethoxazole +Trimethoprim), Azoles and Amphotericin B, Tetracycline (Doxycycline), Nitrofurans (Nitrofurantoin), and others. In terms of revenue, the quinolones segment is expected to hold a major share of the urinary tract infection treatment market during the forecast period since it is widely prescribed and has proven to be safe and effective for antimicrobial use.
Based on indication, the Global Urinary Tract Infection Treatment Industry has been segmented into complicated urinary tract infections and uncomplicated urinary tract infections. Based on distribution channels, the urinary tract infection treatment market has been categorized into hospital pharmacies, gynecology & urology clinics, drug stores, retail pharmacies, and online drug stores. The retail pharmacies segment is expected to exhibit high revenue growth in the Global Urinary Tract Infection Treatment Industry owing to the easy availability of antibiotics.
Key Players operating in the Global Urinary Tract Infection Treatment Industry are
- Allergan
- Bayer AG
- Pfizer, Inc.
- GlaxoSmithKline plc
- Bristol-Myers Squibb Company
- Janssen Global Services, LLC
- Lupin Ltd
- Merck & Co., Inc.
- Almirall, S.A
- Dr. Reddy’s Laboratories Ltd.
Click Here To Buy Your Full Report
https://www.futuremarketinsights.com/checkout/1340
Global Urinary Tract Infection Treatment Industry – Key Segments
By Drug Class:
- Penicillin & Combinations
- Quinolones
- Cephalosporin
- Aminoglycoside Antibiotics
- Sulphonamides (Sulfamethoxazole, Trimethoprim)
- Azoles and Amphotericin B
- Tetracycline (Doxycycline)
- Nitrofurans (Nitrofurantoin)
- Others
By Indication:
- Complicated
- Uncomplicated
By Distribution Channel:
- Hospital Pharmacies
- Gynecology and Urology Clinics
- Drug Stores
- Retail Pharmacies
- Online Drug Stores
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- South Asia and Pacific
- East Asia
- Middle East and Africa
Author:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
